Introduction: Lung cancer is the leading cause of cancerrelated deaths worldwide. ALK receptor tyrosine kinase gene (ALK) rearrangement has been identified in 3% to 5% of patients with NSCLC. The most common ALK rearrangement is echinoderm microtubule associated protein like 4 (EML4)-ALK, with several variants that can be targeted by the tyrosine kinase inhibitor crizotinib.
Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide, in which approximately 80% are NSCLC. 1 Chromosome rearrangement involving the ALK receptor tyrosine kinase gene (ALK) has been identified in 3% to 5% of patients with NSCLC. 2, 3 In NSCLC, the most common ALK fusion partner is echinoderm microtubule associated protein like 4 gene (EML4). 1 Other ALK fusion partners discovered in NSCLC include kinesin family member 5B gene (KIF5B), kinesin light chain 1 gene (KLC1), TRK-fused gene (TFG), translocated promoter region, nuclear basket protein gene (TPR), Huntington interacting protein 1 gene (HIP1), and dynactin-1 gene (DCTN1). 4 Crizotinib, a small molecular tyrosine kinase inhibitor of ALK receptor tyrosine kinase (ALK), ROS1, and mesenchymal-epithelial transition, has been approved by the U.S. Food and Drug Administration for ALK-positive NSCLC. 5 Compared with traditional techniques such as fluorescence in situ hybridization or the immunohistochemistry method, 6 next-generation sequencing (NGS) has been increasingly commonly used in the molecular diagnosis of gene fusions in clinical cancer samples, especially for de novo finding. 7, 8 In this study, through use of targeted NGS, a novel ALK fusion partner, cut-like homeobox 1 gene (CUX1), has been identified in a patient with NSCLC, and further studies have shown that the novel CUX1-ALK fusion gene might represent a potential therapeutic target for crizotinib.
Materials and Methods
The patient gave written consent for specimen collection and genetic testing. Both tumor and blood specimens were collected and prepared as per standard protocols approved by the ethics committee of the First Affiliated Hospital of Nanjing Medical University. Tumor genomic DNA was extracted from formalin-fixed paraffin-embedded (FFPE) sections followed by targeted NGS sequencing as previously described. 9 Sequencing data were mapped onto human hg19, and genomic fusions were identified by using the Fusion and Chromosomal Translocation Enumeration and Recovery Algorithm with default parameters. Total RNA extracted from FFPE sections was subjected to RNA sequencing on the Illumina HiSeq 4000 platform (Illumina, San Diego, CA). In reverse-transcriptase polymerase chain reaction (PCR) experiments, a complementary DNA (cDNA) library was synthesized from total RNA extracted and amplified in the subsequent PCR experiments with a primer pair flanking the two fusion points in the CUX1-ALK fusion gene.
Human EML4-ALK variant 1 cDNA and CUX1-ALK fusion cDNA were cloned into the empty vector pcDNA3 and transiently transfected into cells of the line 293T in the presence of FuGENE transfection reagent (Promega, Madison, WI). Twenty-four hours after transfection, cells were serum-starved for 24 hours and treated with 1 mM crizotinib or vehicle control for the indicated time points. Cells were lysed, and total protein was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and analyzed by Western blot analysis with the antibodies listed in Supplementary Table 1 .
Results
Detection of a Novel CUX1-ALK Fusion Gene in a Patient with NSCLC A 66-year-old Chinese man was determined to have an abnormally high carcinoembryonic antigen (CEA) level (22.24 ng/mL) in a routine physical examination in July 2012 (Fig. 1A) . In August 2012, computed tomography (CT) scans revealed a nodule (1.18 Â 1.04 cm) at the lower lobe of the left lung (see Fig. 1A ). Videoassisted thoracoscopic surgery was performed to remove the primary tumor and was followed by adjuvant chemotherapy treatment. Pathologic analysis indicated poorly differentiated lung adenocarcinoma. In November 2013, enlarged lymph nodes were found in front of the carina (Fig. 1B) , and the patient's CEA level reached 18.29 ng/mL (Fig. 1D ). On the basis of these symptoms, recurrence was considered in the patient. From November 2013 to April 2014, the patient was given five cycles of chemotherapy. However, his CEA level remained high, reaching 42.7 ng/mL in July 2015, although no metastasis was seen on his CT scans.
In July 2015, FFPE sections of the primary tumor were subjected to comprehensive NGS with a pan-cancer gene panel. 9 The mutation profile showed a rearrangement between chromosome 2 and chromosome 7 with a mutant allele frequency of 11% ( Fig. 2A) . The fusion gene consisted of the 5 0 terminus of CUX1 (exon 1 to intron 8) and 3 0 terminus of ALK (nucleotide 54 of exon 20 to exon 29) (Fig. 2B ). Because exon 8 of CUX1 ends at the second nucleotide on a codon whereas nucleotide 54 of exon 20 of ALK starts in a new codon, a reading frame shift would result if the two reading frames were directly joined. To unravel the transcript sequence of the fusion gene, we established RNA sequencing to capture the fusion mRNA. As shown in Figure 2C , a 97-nucleotide RNA sequence transcribed from intron 8 of CUX1 immediately upstream of the breakpoint was inserted between the two transcripts of CUX1 and ALK, which avoids the reading frame shift, as indicated in Figure 2B .
The fusion transcript was further confirmed by reverse-transcriptase PCR with primers flanking the 97-nucleotide intron sequence. As shown in Figure 2D , PCR products were obtained from the cDNA library prepared from tumor specimens at the expected size, whereas no products were obtained from the patient's whole blood control, indicating that this fusion gene was present only in the tumor cells. Furthermore, Sanger sequencing of the PCR products confirmed that the two breakpoints and fusion sequence were in compliance with our hypothesis (Fig. 2E) .
Activation of ALK Downstream Signaling Pathways Driven by CUX1-ALK Fusion Protein
To determine whether this novel ALK fusion protein is involved in oncogenesis, transformation assay was performed in Ba/F3 cells. After interleukin-3 (IL-3) depletion, Ba/F3 cells carrying CUX1-ALK, as well as EML4-ALK, showed IL-3-independent growth compared with the cell death in cells carrying the blank vector in the absence of IL-3 ( Supplementary Fig. 1 ). Furthermore, self-phosphorylation of cut-like homeobox 1 (CUX1)-ALK fusion protein and activation of the ALK downstream signaling pathways were examined. As shown in Figure 3A , the two ALK fusion proteins could be selfphosphorylated at position Y1604, which could be inhibited by addition of the ALK tyrosine kinase inhibitor crizotinib, suggesting that these ALK fusions are sensitive to an ALK inhibitor. Hyperactivation of both MEK1/2 and ERK1/2 was observed in cells carrying ALK fusions, as indicated by the significantly increased phosphorylation levels (Fig. 3B) . The addition of crizotinib partially inhibited the phosphorylation of MEK1/2 and ERK1/2 in cells harboring EML4-ALK. However, the inhibition was not affected in CUX1-ALK-expressing cells upon crizotinib inhibition, suggesting that the CUX1-ALK fusion protein might have a longer half-life on activation of mitogen-activated kinase signaling pathways than EML4-ALK does and might require a higher concentration of the drug or longer treatment for inhibition.
As shown in Figure 3C and D, phosphorylation of signal transducer and activator of transcription 3 and AKT T308/S473 was increased in the presence of EML4-ALK and CUX1-ALK, respectively, and inhibited by crizotinib treatment. These data suggest that CUX1-ALK could conduct self-phosphorylation and further cause hyperactivation of the downstream mitogen-activated protein kinase, Janus kinase-signal transducer and activator of transcription, and phosphoinositide 3-kinase/ AKT pathways.
CUX1-ALK as a Potential Therapeutic Target
The patient was orally administrated crizotinib at a dose of 250 mg twice a day because of identification of the CUX1-ALK fusion gene. One month after treatment, the patient's CEA level dropped from 42.7 ng/mL to 13.7 ng/mL and remained less than 6 ng/mL for a period of 14 months (from November 2015 to December 2016); this decrease in CEA level was accompanied by a relief of clinical symptoms. Upon crizotinib treatment, the level of circulating tumor DNA (ctDNA) in the patient's blood was monitored every 3 to 5 months and the CUX1-ALK fusion gene was no longer detected. In total, the patient achieved progressive-free survival for 20 months (from August 2015 to March 2017). In the 21 months of crizotinib treatment, suspected metastasis was seen in the left lower kidney on CT scans (Fig. 1C) , with an increased level of CEA (at 13.51 ng/mL) (see Fig. 1D ). Crizotinib was then discontinued, and chemotherapy was administrated in May 2017.
Discussion
ALK has been found to be fused with a number of genes in a variety of human cancers. 4 Mechanisms of tumorigenesis driven by ALK fusion proteins likely involve constitutive, ligand-independent activation of the ALK kinase mediated by the fusion partner through oligomerization. 4 In NSCLC, EML4-ALK is the most common and best-studied ALK rearrangement, 10 and the discovery of rare ALK fusion partners such as KIF5B-ALK 11 and KLC1-ALK 12 triggered attempts to identify more partner genes of ALK and further seek personalized treatment solutions for the maximum benefit to patients with NSCLC.
To our knowledge, CUX1 has not been reported previously as a fusion partner of ALK. Cases of CUX1-fibroblast growth factor receptor 1 gene (FGFR1) (C11:F10) and CUX1-ret proto-oncogene gene (RET) (C10:R12) fusion have been reported in T-lymphoblastic leukemia/lymphoma and in lung cancer, respectively. CUX1 is a transcriptional regulator containing an N-terminal coiled-coil domain, indicating that the CUX1 is likely to drive the dimerization of the CUX1-ALK, CUX1-FGFR1, and CUX1-RET fusion proteins and further activate the self-phosphorylation of these receptor tyrosine kinases and trigger downstream signaling pathways. 13 In our study, this hypothesis has been validated by CUX1-ALK in 293T cells and further , and CUX1-ALK, respectively, were serum-starved for 24 hours, followed by treatment with DMSO (0) or 1 mM crizotinib for indicated time points. Cell lysates were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis separation and immunoblotting analysis with the antibodies listed in Supplementary Table 1 . Results are shown for one of two biological replicates. pALK, phosphorylated ALK receptor tyrosine kinase; pMEK1/2, phosphorylated MEK1/2; pERK1/2, phosphorylated ERK1/2; pSTAT3, phosphorylated signal transducer and activator of transcription 3.
supported by the patient's positive therapeutic response to crizotinib. In addition, compared with fluorescence in situ hybridization, which is the criterion standard for clinical diagnosis of ALK rearrangement, NGS gave the advantage to high-throughput screening and de novo discovery.
Resistance to crizotinib usually occurs after approximately 10 months of treatment. In this case, the patient had a superior response to crizotinib, with a 20-month progression-free survival. Within this period, the CUX1-ALK fusion fragment was absent in close genetic monitoring of ctDNA. However, the patient eventually experienced development of kidney metastasis without any known driver mutations detected in his ctDNA. Further studies need to be performed to explore the mechanisms of crizotinib resistance in this case. In summary, we have identified a rare CUX1-ALK fusion gene with a short DNA fragment inserted between the two fusion genes and demonstrated the oncogenic role of this fusion gene in 293T cells. The patient's positive response to crizotinib has provided new insight into lung cancer therapy.
